One Shot: The Promise and Peril of Single-Infusion HIV Treatments

Two participants in a clinical trial at the University of California, San Francisco stopped taking their daily antiretroviral pills after receiving a single infusion of engineered immune cells. Two years later, their HIV remained undetectable [1]. The results, presented at the American Society of Gene and Cell Therapy meeting in Boston, have generated immediate excitement — and immediate skepticism. If a single infusion can replace a lifetime of daily medication, the implications for the 39.9 million people living with HIV worldwide are enormous [2]. But the distance between a proof-of-concept in two patients and a scalable global therapy is vast, and the history of HIV treatment is littered with breakthroughs that failed to reach the people who need them most.

Source: UNAIDS

Data as of Jul 1, 2025CSV

What the Treatment Is and What the Trial Showed

The UCSF approach, led by Dr. Steve Deeks, involves extracting a patient's own immune cells, genetically engineering them to recognize HIV-infected cells, and infusing them back into the patient [1]. This is a form of adoptive cell therapy — conceptually similar to CAR-T treatments used in certain cancers. After infusion, participants underwent an analytical treatment interruption, stopping their antiretroviral therapy (ART) to see whether the engineered cells could control the virus on their own.

Two participants maintained undetectable viral loads for up to two years [1]. Deeks described the results as "inspiration and a potential road map to get to where we need to go" [1]. The trial remains small, and the full dataset has not yet been published in a peer-reviewed journal. The treatment is best understood as a proof of concept rather than a ready-to-deploy therapy.

This approach is distinct from — but complementary to — another major line of research: broadly neutralizing antibodies, or bNAbs. These are laboratory-produced antibodies that target conserved regions of HIV's surface proteins, the sites where the virus is least able to mutate without losing its ability to infect cells. Multiple bNAb trials have reported results in the past two years, with varying degrees of success.

Broadly Neutralizing Antibodies: The Other Single-Infusion Strategy

In a Phase 1/2a trial published in Nature Medicine, a triple bNAb combination — PGT121, PGDM1400, and VRC07-523LS — maintained virologic suppression in 83% of participants during active antibody therapy [3]. More striking, 42% of participants continued to show suppression for 38 to 44 weeks even after serum antibody levels had declined to low or undetectable concentrations [3]. This suggests the antibodies may have done more than passively suppress viral replication — they may have engaged the immune system in ways that provided sustained benefit.

Trials of two other bNAbs, 3BNC117 and 10-1074, have shown similar results. In one study, 13 of 17 ART-suppressed participants maintained virologic suppression for at least 20 weeks after stopping ART, and two individuals maintained suppression past one year [4]. When these antibodies were combined with lenacapavir, Gilead's long-acting capsid inhibitor, only one out of 21 participants experienced viral rebound over at least 26 weeks [4].

The academic research pipeline behind these therapies is substantial. More than 39,000 papers on broadly neutralizing antibodies and HIV have been published since 2011, with output peaking at 4,743 papers in 2023 [5].

Source: OpenAlex

Data as of Jan 1, 2026CSV

How a Single Infusion Sustains Years of Suppression

The biological mechanisms differ across these approaches, and the mechanism determines both the ceiling on durability and the nature of failure.

The UCSF engineered cell therapy works through what is essentially a living drug: the modified immune cells can persist in the body, divide, and mount ongoing responses to HIV-infected cells [1]. If they engraft successfully and maintain their function, they could provide indefinite suppression. But if they lose potency over time — a documented problem with CAR-T therapies in cancer — the virus will rebound.

Broadly neutralizing antibodies work through passive immunity. The infused antibodies circulate in the bloodstream, binding to free virus and to infected cells. Their half-lives vary — engineered versions like 3BNC117-LS and 10-1074-LS have extended half-lives designed to last months rather than weeks [4]. But antibodies are eventually cleared by the body, and once serum levels drop below a therapeutic threshold, the virus can rebound. The 42% of patients who maintained suppression well past antibody clearance in the triple bNAb trial may have experienced an additional immune-mediated effect — the antibodies may have helped cytotoxic T cells (CD8+ cells) mount a stronger response to the viral reservoir [3].

Neither approach permanently alters the HIV reservoir in the way a stem cell transplant does. Both are best classified as long-duration suppression tools requiring eventual retreatment, not curative interventions.

The Failure Mode: Viral Escape

HIV's genetic diversity is the central obstacle. The virus mutates rapidly, and any therapy that relies on targeting specific viral surface features risks selecting for resistant variants.

A 2026 study in Nature Microbiology mapped more than 100 escape mutations across 15 HIV-1 strains tested against bNAbs 3BNC117 and 10-1074 [6]. For 12 of those 15 strains, a single amino acid change was sufficient to confer resistance [6]. The escape pathways for 10-1074 were particularly restricted — a small number of documented mutations appeared repeatedly across different viral strains [7].

This is the core tension: the same conserved viral sites that make bNAbs effective are also the sites where escape mutations, though constrained, are not impossible. Combination strategies — using two or three bNAbs targeting different epitopes — substantially reduce the probability of escape. A virus that escapes one antibody must simultaneously escape the others, which requires multiple independent mutations. But combination strategies do not eliminate the risk entirely [6].

For the engineered cell therapy, the escape dynamics are less well characterized. If the engineered cells target a single viral epitope, the same single-mutation escape problem applies. If they target multiple epitopes or function through broader immune mechanisms, the resistance barrier may be higher.

A critical question for both approaches: when suppression does break down, does the rebounding virus carry resistance mutations that compromise salvage treatment options? The available data suggest that bNAb-resistant viruses generally remain sensitive to conventional antiretroviral drugs [4]. But larger trials and longer follow-up are needed to confirm this.

Who Was in the Trials — and Who Was Not

The existing trial populations are small and not fully representative of the global HIV epidemic. The UCSF engineered cell therapy trial has reported results from only two participants, making any demographic analysis impossible at this scale [1].

The bNAb trials have been somewhat larger but still limited. The triple bNAb Phase 1/2a trial included participants who were ART-suppressed and had viruses pre-screened for sensitivity to the administered antibodies [3]. This pre-screening is itself a significant limitation — it means the therapy was tested primarily in patients whose viruses were already known to be susceptible, not in an unselected population.

The Tatelo study, which tested VRC01LS plus 10-1074 in children, found that 44% maintained viral suppression through 24 weeks of bNAb-only treatment [4]. Data from women, people who inject drugs, older patients, and those with pre-existing resistance mutations remain sparse across these trials. Given that sub-Saharan Africa carries roughly two-thirds of the world's HIV cases [2] and that women account for the majority of new infections in the region, the absence of representative trial populations is a significant gap.

The Cost Problem

The economics of single-infusion therapies present a paradox. A treatment that replaces years of daily medication should, in theory, be cheaper over the long run. In practice, the manufacturing complexity of both engineered cell therapies and monoclonal antibodies makes them among the most expensive categories of medicine.

Source: UNAIDS / aidsmap

Data as of Jan 1, 2025CSV

First-line generic antiretroviral treatment costs an average of $95 per person per year in low- and middle-income countries (LMICs), down from approximately $10,000 in 2000 [8][9]. In the United States, branded combination pills like Biktarvy carry list prices around $45,000 per year [10]. Second-line treatment in LMICs averages $256 per year but reaches $1,494 in upper-middle-income countries in Latin America [11].

Engineered cell therapies are currently priced in the hundreds of thousands of dollars per treatment in oncology settings. CAR-T therapies for cancer typically cost $373,000 to $475,000 per infusion in the United States. bNAb production, while less expensive than cell therapy, still involves complex biomanufacturing. An analysis published in aidsmap found that injectable HIV therapies would need to cost less than $131 per year to be cost-effective in Africa [12] — a target that current bNAb manufacturing costs are unlikely to meet without substantial scale-up and process innovation.

Approximately 80% of generic antiretroviral medicines procured by LMICs are manufactured in India [8]. Whether Indian generic manufacturers could produce bNAbs at comparable scale remains an open question. Monoclonal antibody biosimilar production is expanding globally, but the regulatory and manufacturing infrastructure for bNAbs at the volumes required for HIV treatment does not yet exist.

The Cabenuva Precedent: Why Access Cannot Be Assumed

The most direct precedent for a long-acting HIV therapy reaching market is cabotegravir plus rilpivirine (Cabenuva), approved in 2021 as the first long-acting injectable HIV treatment — administered every two months rather than daily [13]. It was widely described at launch as a major advance in convenience and adherence. Five years later, its global reach remains limited.

ViiV Healthcare committed to making at least 2 million doses of long-acting cabotegravir for pre-exposure prophylaxis (PrEP) available in LMICs during 2025-2026, tripling supply compared to 2024 [13]. The company extended its voluntary licensing agreement with the Medicines Patent Pool to cover 133 countries, with licensees including Aurobindo, Cipla, and Viatris [14]. But generic versions of injectable cabotegravir/rilpivirine are not expected before 2027 [13], creating an affordability bottleneck that has persisted for years.

A trial published in the New England Journal of Medicine confirmed that cabotegravir plus rilpivirine is as effective as dolutegravir-based oral treatment in sub-Saharan African adults with a history of treatment non-adherence [15]. The efficacy data exist. The access infrastructure does not.

This precedent matters because single-infusion bNAb or cell therapies would face the same set of obstacles at greater intensity: higher manufacturing complexity, more stringent cold-chain requirements, and the need for clinical infrastructure (infusion centers, monitoring) that is sparse in the regions with the highest HIV burden.

Patents, Licensing, and the Question of Equitable Access

The Medicines Patent Pool (MPP), established in 2010, has been the primary mechanism for negotiating voluntary licenses that enable generic production of HIV medicines in LMICs. Its track record is substantial: over 1 billion packs of generic dolutegravir-based medicines have reached 24 million people in 128 LMICs, with a projected cost-benefit ratio of 1:43 — meaning total savings will be approximately 43 times the funds used to execute the MPP's mission by the end of 2028 [16].

For newer long-acting therapies, licensing agreements are expanding. Gilead entered voluntary licensing agreements for lenacapavir in 120 LMICs in October 2024 [17]. ViiV extended its cabotegravir licensing to 133 countries through the MPP [14].

For the bNAb therapies and engineered cell therapies currently in trials, patent and licensing arrangements are less clear. The triple bNAb combination (PGT121, PGDM1400, VRC07-523LS) was developed through academic-industry partnerships involving institutions like the International AIDS Vaccine Initiative (IAVI), the National Institutes of Health, and Scripps Research [3]. The 3BNC117 and 10-1074 antibodies were developed at Rockefeller University [6]. Whether these antibodies will be licensed through the MPP or through bilateral agreements with generic manufacturers has not been publicly announced.

The UCSF engineered cell therapy is at an even earlier stage. Autologous cell therapies — where each patient's own cells must be individually processed — are inherently difficult to genericize. The manufacturing process is the product, and it does not lend itself to the same economies of scale that drove generic antiretroviral pill prices below $100 per year.

Comparison to Functional Cures and Vaccines

The only confirmed cures of HIV have come through allogeneic hematopoietic stem cell transplants from donors carrying homozygous mutations in the CCR5 gene — the receptor HIV uses to enter cells. Timothy Ray Brown (the Berlin Patient) and Adam Castillejo (the London Patient) both received transplants for concurrent blood cancers and both achieved sustained HIV remission [18]. A 2025 paper in Nature reported sustained remission even with a heterozygous CCR5-delta32 donor, broadening the potential donor pool [19]. But stem cell transplantation carries substantial mortality risk and requires a concurrent indication like cancer. It is not a scalable strategy.

mRNA-based HIV vaccine development is progressing along a separate track. The IAVI G004 Phase 1 trial, which began dosing participants in Soweto, South Africa in December 2025, tests three mRNA immunogens delivered using Moderna's platform [20]. The goal is to train the immune system to produce its own broadly neutralizing antibodies. A proof-of-concept study published in Science showed that a stepwise vaccination strategy could advance human immune responses toward generating bNAbs [21], and a separate trial showed that mRNA-encoded HIV envelope trimers could elicit tier 2 neutralizing antibodies — a milestone indicating protection against real-world HIV strains [22].

These vaccine candidates aim for prevention rather than treatment of established infection. They complement rather than compete with single-infusion therapeutic approaches. If a vaccine could prevent new infections while single-infusion therapies suppressed the virus in those already infected, the combination could significantly accelerate progress toward epidemic control.

The Steelman Case for Skepticism

The strongest argument against expecting these therapies to transform HIV treatment at scale rests on structural rather than scientific grounds.

First, the trial populations are tiny. Two patients in the UCSF cell therapy trial and a few dozen in the bNAb trials do not constitute the evidence base required for regulatory approval, let alone global deployment. Phase 3 trials will take years, and results may not replicate as the participant pool broadens to include people with more diverse viral subtypes and clinical histories.

Second, manufacturing scale-up for biologics is a different order of difficulty than for small-molecule pills. Generic antiretroviral pills are cheap because the chemistry is straightforward and the manufacturing infrastructure in India and elsewhere has been built over two decades [8]. Monoclonal antibody and cell therapy manufacturing requires specialized facilities, trained personnel, and quality control systems that most LMICs do not have. Even with voluntary licensing, the gap between a license and actual affordable production could be a decade or more.

Third, the Cabenuva precedent is instructive. Five years after approval, long-acting injectable cabotegravir remains largely unavailable in sub-Saharan Africa [13]. The reasons — supply constraints, cost, infrastructure requirements — apply with greater force to infusion-based therapies.

Fourth, viral escape is not a hypothetical risk. More than 100 documented escape mutations exist for just two bNAbs [6]. Deploying bNAb therapy at scale could select for resistant viral populations in the same way that incomplete antiretroviral rollouts in the 2000s selected for drug-resistant HIV.

What Comes Next

The UCSF engineered cell therapy and the bNAb combination trials represent genuine scientific progress. They demonstrate that durable HIV suppression without daily medication is biologically achievable. But achievability in controlled settings and accessibility for the populations who need these therapies most are different problems, separated by manufacturing capacity, cost reduction, regulatory approval, and health system infrastructure.

The most realistic near-term path may involve combining bNAbs with long-acting antiretrovirals like lenacapavir. The combination trial showing only one rebound in 21 participants over 26 weeks suggests this hybrid approach could offer long-duration suppression with a lower risk of viral escape than bNAbs alone [4]. Lenacapavir is already FDA-approved as a twice-yearly injection [23], and Gilead has extended voluntary licensing to 120 LMICs [17].

The next milestones to watch: peer-reviewed publication of the UCSF cell therapy data, Phase 2/3 expansion of the bNAb combination trials, and — critically — pricing announcements that indicate whether these therapies can be made available at costs that LMIC health systems and international donors can sustain. The science has arrived at a promising threshold. Whether the infrastructure, economics, and political will follow remains the open question.